INCONTESTABLE® Blog
April 19, 2024
Webinar
Advertising Self-Regulation in 2024: Q&A with NAD Vice President Laura Brett
January 30, 2024
Never miss an Insight.
Sign upArticles
Southeast Litigation Update: February 2024 Southeast Litigation Update: February 2024
April 15, 2024
Articles
Southeast Litigation Update: January 2024 Southeast Litigation Update: January 2024
March 7, 2024
Articles
Potential Implications of Inflation Reduction Act on Pharmaceutical Patent Litigation Potential Implications of Inflation Reduction Act on Pharmaceutical Patent Litigation
May 1, 2023
Bloomberg LawProsecution First Blog
The Eastern District of Arkansas Holds Key Claim Terms Indefinite in Enviro Tech. v. Safe Foods Corp. The Eastern District of Arkansas Holds Key Claim Terms Indefinite in Enviro Tech. v. Safe Foods Corp.
March 3, 2023
IP Health Blog
FDA Guidance on Quality Considerations for Clinical Research Involving Cannabis and Cannabis-Derived Compounds FDA Guidance on Quality Considerations for Clinical Research Involving Cannabis and Cannabis-Derived Compounds
February 24, 2023
Federal Circuit IP Blog
Spotlight on Upcoming Oral Arguments – February 2023 Spotlight on Upcoming Oral Arguments – February 2023
February 3, 2023
Prosecution First Blog
Federal Circuit Clarifies the Standard of Review for Invalidity Challenges Federal Circuit Clarifies the Standard of Review for Invalidity Challenges
January 13, 2023
At the PTAB Blog
PTAB Denies IPR Challenging Patent Relating to a Prenatal Vitamin PTAB Denies IPR Challenging Patent Relating to a Prenatal Vitamin
November 22, 2022
Articles
Protecting Your Company’s IP in an Emerging Market Protecting Your Company’s IP in an Emerging Market
November 9, 2022
Marijuana VentureArticles
Patenting Treatments Involving Schedule I Substances Patenting Treatments Involving Schedule I Substances
October 17, 2022
Pharmaceutical OnlineAt the PTAB Blog
PTAB Invalidates United Therapeutics Patent Relating to the Hypertension Drug - Tyvaso® PTAB Invalidates United Therapeutics Patent Relating to the Hypertension Drug - Tyvaso®
September 21, 2022
Articles
Latest Developments in IP Strategies for Pharmaceuticals Latest Developments in IP Strategies for Pharmaceuticals
Summer 2022
International Pharmaceutical IndustryDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.